March 26, 2015

The House Energy & Commerce Health subcommittee held a hearing on the 340B Drug Pricing Program to “review the functionality of the program to ensure it is meeting its intended goals.” Hospitals, the pharmaceutical industry, and other program participants must be prepared for changes to the program, as the Health Service Resources Administration (HRSA) intends to issue program guidance later this year. HRSA also intends to issue a Notice of Proposed Rulemaking that will address civil monetary penalties and drug ceiling prices within the 340B program.

The Energy & Commerce Committee may revisit HRSA’s statutory authority over the 340B program and the hearing is an indication of the committee members’ thoughts on the program’s administration as well as the committee’s oversight role.

To view the full alert, click here.